Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...

The Lung Association's eighth annual "State of Lung Cancer" report highlights how the toll of lung cancer varies by state and examines key indicators throughout the U.S., including new cases, survival ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

Data from the non-pivotal stage of the global Phase 3 PRESERVE-003 trial revealed that gotistobart reduced the risk of death by 54% compared to docetaxel chemotherapy. The 12-month survival rate was ...

Kentucky is witnessing a transformative improvement in lung cancer outcomes, with a notable 30% increase in survival rates ...

Raymond Osarogiagbon, MD, highlights the potential benefits of increasing screening rates for patients diagnosed with lung cancer and the broader US health care system. In part 2 of an interview ...

There is no evidence of a lasting impact on early cancer survival or mortality in Ireland due to the disruption caused by the ...

American Lung Association's 'State of Lung Cancer' report reveals new national lung cancer data, calls on states to ensure access to care The Lung Association's eighth annual "State of Lung Cancer" ...

The MarketWatch News Department was not involved in the creation of this content. American Lung Association's 'State of Lung Cancer' report reveals new national lung cancer data, calls on states to ...